Please read Dr. Panettieri’s article in the New England Journal of Medicine titled, “Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma.“
Asthma is a heterogeneous disease that manifests as variable airflow obstruction with recurring symptoms driven by underlying persistent, yet fluctuating, airway inflammation. During a loss of asthma control, patients often focus on obtaining immediate symptom relief by relying on their rescue medication, typically a short-acting β2-agonist (SABA). However, SABAs have little effect on underlying airway inflammation, and overreliance on SABAs serves as a metric for poor asthma control, with an associated risk of severe asthma exacerbation. Because severe asthma exacerbations contribute to considerable morbidity and mortality, the prevention of exacerbations is imperative in the management of asthma. To read the full article.
Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma. Papi A, Chipps BE, Beasley R, Panettieri RA Jr, Israel E, Cooper M, Dunsire L, Jeynes-Ellis A, Johnsson E, Rees R, Cappelletti C, Albers FC. N Engl J Med. 2022 May 15. PMID: 35569035 DOI: 1056/NEJMoa2203163 Online ahead of print.